HD-OPM Archive
Hashtags

#budoff

15 posts

Colchicine 0.5 mg cut plaque volume by over 1% in one year on CT angiography (Budoff)

May 11, 2025 · Louis Nervegna ♥ 20 · 💬 37 ↩ 9 Plaque, CAC & CT angiography

Louis highlights a Budoff-led CCTA trial in which low-dose colchicine reduced percent atheroma volume by over 1% in a year, with lower CRP and a slowing of calcified plaque. He contrasts this with the Keto-CTA study, where PAV rose 0.8% on a keto diet. Budoff notes it was a small study but supports colchicine in chronic stable coronary disease.

Budoff recommends statins, aspirin and BP control for keto dieters with CT-detected plaque

Apr 14, 2025 · Louis Nervegna ♥ 14 · 💬 15 Low-carb, keto & carnivore

Louis cites a video in which Keto-CTA principal investigator Matthew Budoff recommends statins, low-dose aspirin and tight blood pressure control for patients on keto diets with significant plaque on CT angiography, and CT scans for his ketogenic patients. He says the statin is to treat plaque, since statins slow plaque progression even at low LDL.

Keto-CTA plaque progression vs plaque regression on Repatha in Budoff's other study

Apr 09, 2025 · Louis Nervegna ♥ 8 · 💬 2 Plaque, CAC & CT angiography

Louis compares non-calcified plaque volume (NCPV) changes in the Keto-CTA (LMHR) study with a second Matthew Budoff study in higher-risk people whose LDL was lowered to about 30 mg/dL with the PCSK9 inhibitor Repatha. The lean, healthy keto group with LDL 254 mg/dL progressed, while the hypertensive, higher-risk Repatha group mostly showed major regression. He also notes that uL and mm^3 are the same unit when comparing NCPV across studies.

Repatha alone reversed soft plaque in 37 of 47 patients over 18 months at LDL near 30

Nov 13, 2026 · Louis Nervegna ♥ 9 · 💬 1 PCSK9, ezetimibe & newer drugs

Louis explains a small uncontrolled study of the PCSK9 inhibitor evolocumab with CT angiography. Average LDL was about 30 mg/dL, 37 of 47 patients had some non-calcified plaque regression, and many had large reversals worth years of typical growth (about 5 mm3 per year). He cautions it was small with no randomization or control group, and that PCSK9 monotherapy is not yet proven to reduce heart attacks.

Keto-CTA omitted its primary plaque outcome: median NCPV rose 18.8 mm3, 2.5x forecast

Apr 13, 2025 · Louis Nervegna ♥ 6 Plaque, CAC & CT angiography

Louis quotes Alex Leaf's critique: the Keto-CTA paper barely mentioned non-calcified plaque volume (NCPV), the primary outcome, saying only 'most participants presented with stable NCPV'. The lead author later gave a median increase of 18.8 mm3, over 2.5x the 7 mm3 predicted, comparable to metabolic syndrome over 3 years or type 2 diabetes per year, and nearly 3x SMARTool high-risk non-statin users.